Heteroaromatic glucokinase activators

Abstract

The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators which increase insulin secretion for the treatment of type II diabetes.

1 .- 24 . (canceled) 
     
     
         25 . A compound of formula I: 
       
         
           
           
               
               
           
         
         wherein, the * indicates an asymmetric atom; 
         R 1  is selected from the group consisting of H, Cl, F, Br, I, NH 2 , —NHOH, —CN, —NO 2 , C 1-6  alkyl, —OR 5 , —C(O)OR 6 , perfluoro-C 1-6  alkyl, C 1-6  alkyl-S—, perfluoro-C 1-6  alkyl-S—, C 1-6  alkyl-SO 2 —, perfluoro-C 1-6  alkyl-SO 2 —, C 1-6  alkoxy-C 1-6  alkyl-SO 2 —, C 1-6  alkyl-S(O)—, and —SO 2 NR 13 R 14 ; 
         R 2  is selected from the group consisting of C 1-6  alkyl-SO 2 —, C 3-6  cycloalkyl-SO 2 —, perfluoro-C 1-6  alkyl-SO 2 —, and C 1-6  alkoxy-C 1-6  alkyl-SO 2 —; 
         R 3  is cyclopentyl; 
         ring A is a di-substituted thiazole;
 wherein the substituent is selected from: Cl; CF 3 ; C 1-4  alkyl; —(CH 2 ) n —C(O)R 7 ; —(CH 2 ) n —C(O)OH; —(CH 2 ) n —S(O) p —(CH 2 ) n —C(O)NR 10 R 11 ; and —(CH 2 ) n —S(O) p —(CH 2 ) n -5-6 membered heterocycle consisting of carbon atoms and 1-3 heteroatoms selected from S(O) p , O, and N, and N is substituted with 0-1 C 1-4  alkyl; and, 
 
         R 7 , at each occurrence, is independently selected from C 1-4  alkyl and C 3-6  cycloalkyl; 
         R 5 , at each occurrence, is independently selected from the group consisting of H, C 1-6  alkyl, and perfluoro-C 1-6  alkyl; 
         R 6 , at each occurrence, is independently C 1-6  alkyl; 
         R 8 , at each occurrence, is independently selected from the group consisting of H, C 1-8  alkyl, —(CH 2 ) n —OH, —(CH 2 ) n —C(O)OH, aryl, and 5-10 membered heteroaryl consisting of carbon atoms and 1-3 heteroatoms selected from S(O) p , O, and N; 
         R 9 , at each occurrence, is independently selected from the group consisting of H, C 1-8  alkyl, —(CH 2 ) n —OH, —(CH 2 ) n —C(O)OH, aryl, and 5-10 membered heteroaryl consisting of carbon atoms and 1-3 heteroatoms selected from S(O) p , O, and N; 
         alternatively, R 8  and R 9 , together with the nitrogen to which they are attached form a 5-6 membered heterocycle, consisting of, in addition to the nitrogen atom to which R 8  and R 9  are attached, carbon atoms and 0-2 heteroatoms selected from S(O) p , O, and N; 
         R 10 , at each occurrence, is independently selected from the group consisting of H; C 1-6  alkyl; —(CH 2 ) n —OH; —(CH 2 ) n —C(O)OH; —(CH 2 ) n —C 3-8  cycloalkyl; —(CH 2 ) n -aryl; —(CH 2 ) n -5-10 membered heterocycle consisting of carbon atoms and 1-3 heteroatoms selected from S(O) p , O, and N; —(CH 2 ) n -5-10 membered heteroaryl consisting of carbon atoms and 1-3 heteroatoms selected from S(O) p , O, and N; —(CH 2 ) n —NHR 7 ; and —(CH 2 ) p —NR 7 R 7 ; 
         R 11 , at each occurrence, is independently selected from the group consisting of H; C 1-6  alkyl; —(CH 2 ) n —OH; —(CH 2 ) n —C(O)OH; —(CH 2 ) n —C 3-8  cycloalkyl; —(CH 2 ) n -aryl; —(CH 2 ) n -5-10 membered heterocycle consisting of carbon atoms and 1-3 heteroatoms selected from S(O) p , O, and N; —(CH 2 ) n -5-10 membered heteroaryl consisting of carbon atoms and 1-3 heteroatoms selected from S(O) p , O, and N; —(CH 2 ) n —NHR 7 ; and —(CH 2 ) n —NR 7 R 7 ; 
         alternatively, R 10  and R 11 , together with the nitrogen to which they are attached form a 5-6 membered heterocycle, consisting of, in addition to the nitrogen atom to which R 10  and R 11  are attached, carbon atoms and 0-2 heteroatoms selected from S(O) p , O, and N; and wherein the heterocycle thus formed is substituted with 0-2 R 12 ; 
         R 12 , at each occurrence, is independently selected from the group consisting of C 1-6  alkyl, Cl, F, Br, I, NO 2 , —(CH 2 ) n —C(O)OH, NR 8 R 9 , NHS(O) 2 CH 3 , S(O) 2 CH 3 , and S(O) 2 NH 2 ; 
         R 13 , at each occurrence, is independently selected from the group consisting of H and C 1-4  alkyl; 
         R 14 , at each occurrence, is independently selected from the group consisting of H and C 1-4  alkyl; 
         p, at each occurrence, is selected from 0, 1, and 2; and 
         n, at each occurrence, is independently selected from 0, 1, 2, 3, 4, 5, and 6, 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         26 . A compound of  claim 25 , wherein in ring A each substituent is independently selected from the group consisting of: Cl; CH 3 ; —CH 2 —C(O)OR 7 ; —CH 2 —C(O)OH; and —S(O) 2 -piperazine optionally substituted with CH 3 ; and, R 7 , at each occurrence, is independently selected from C 1-2  alkyl. 
     
     
         27 . A compound of  claim 25  wherein n is 1. 
     
     
         28 . A compound of  claim 25  wherein n is 2. 
     
     
         29 . A compound of  claim 25 , wherein R 8  and R 9 , together with the nitrogen to which they are attached form a heterocycle selected from: piperazine, piperidine, homopiperazine, and morpholine. 
     
     
         30 . A compound of  claim 25 , wherein R 10  and R 11 , together with the nitrogen to which they are attached form a heterocycle selected from the group consisting of: piperidine, piperazine, homopiperazine, pyrrolidine, and morpholine. 
     
     
         31 . A compound of  claim 25 , wherein the asymmetric carbon shown is in the R configuration. 
     
     
         32 . A compound of  claim 25  wherein
 R 1  is selected from the group consisting of H, Cl, F, Br, I, perfluoro-C 1-6  alkyl, NO 2 , NH 2 , C 1-6  alkyl-SO 2 —, and —SO 2 NR 13 R 14 ; and, 
 R 2  is C 1-6  alkyl-SO 2 —. 
 
     
     
         33 . A compound of  claim 32 , wherein R 1  is H. 
     
     
         34 . A compound of  claim 32 , wherein R 1  is selected from the group consisting of Cl, CF 3 , and CH 3 . 
     
     
         35 . A compound of  claim 32 , wherein R 1  is H and R 2  is CH 3 —SO 2 —. 
     
     
         36 . A compound selected from the group consisting of:
 {2-[3-Cyclopentyl-2-(4-methanesulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid ethyl ester,   3-Cyclopentyl-2-(4-methanesulfonyl-phenyl)-N-[4-methyl-5-(4-methyl-piperazine-1-sulfonyl)-thiazol-2-yl]-propionamide,   {5-Chloro-2-[3-cyclopentyl-2-(4-methanesulfonyl-phenyl)propionylamino]-thiazol-4-yl}-acetic acid ethyl ester,   {2-[3-Cyclopentyl-2-(4-methanesulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid, and   {5-Chloro-2-[3-cyclopentyl-2-(4-methanesulfonyl-phenyl)propionylamino]-thiazol-4-yl}-acetic acid,   or a pharmaceutically acceptable salt thereof.   
     
     
         37 . A pharmaceutical composition comprising: a pharmaceutically acceptable carrier and a compound of  claim 25  or a pharmaceutically acceptable salt thereof.